MedDataX Logo

Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders

NCT ID: NCT06848530

Last Updated: 2025-11-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-30

Study Completion Date

2030-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement disorders. This study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (DBS). Recordings are made from the scalp with a noninvasive electrode and/or through the DBS stimulator if the participant has a stimulator model that is able to sense brain activity. These recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Movement Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants without Deep Brain Stimulators

Multimodal neurophysiology (for example, electroencephalography and electromyography) will be measured during the following:

Movement disorder medication administration -The patient's movement disorders medications, prescribed by their treating physicians outside of this study, may be administered during an experimental session.

Group Type EXPERIMENTAL

Prescribed Medications

Intervention Type OTHER

participant's movement disorders medications, prescribed by their treating physician

Participants with Deep Brain Stimulators

Multimodal neurophysiology (for example, electroencephalography and electromyography) will be measured during the following:

Movement disorder medication administration -The patient's movement disorders medications, prescribed by their treating physicians outside of this study, may be administered during an experimental session.

Deep brain stimulator (DBS) adjustment - Participants who have had deep brain stimulation implantation as part of their standard-of-care clinical treatment may participate in this study. The patient's stimulator may be adjusted within normal clinical limits during an experimental session.

Group Type EXPERIMENTAL

Prescribed Medications

Intervention Type OTHER

participant's movement disorders medications, prescribed by their treating physician

Deep brain stimulation adjustment

Intervention Type OTHER

Deep brain stimulator parameters may be adjusted within normal clinical limits

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prescribed Medications

participant's movement disorders medications, prescribed by their treating physician

Intervention Type OTHER

Deep brain stimulation adjustment

Deep brain stimulator parameters may be adjusted within normal clinical limits

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years of age and above
* Any patient who has been diagnosed by a movement disorders neurologist with one of the following movement disorders:
* Parkinson's disease
* Dystonia
* Tremor, including essential tremor
* Cerebellar ataxia
* Other hyperkinetic movement disorders, such as chorea and tics

Exclusion Criteria

\- Patients with dementia
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pennsylvania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lauren Hammer

Assistant Professor of Neurology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pennsylvania Hospital

Philadelphia, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lauren Hammer, MD, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

857558

Identifier Type: -

Identifier Source: org_study_id